Amneal Pharmaceuticals reports significant revenue and EBITDA growth in Q1 2024, driven by new product launches and strong market performance.
BRIDGEWATER, N.J., May 03, 2024--AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
BRIDGEWATER, N.J., April 24, 2024--Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose